<div id="readability-page-1"><p>World Investment Advisors purchased a new stake in  Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 16,290 shares of the company's stock, valued at approximately $1,664,000.</p><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>Several other large investors have also made changes to their positions in GH. AQR Capital Management LLC grew its stake in shares of  Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company's stock valued at $3,012,000 after buying an additional 25,831 shares in the last quarter.  Empowered Funds LLC bought a new stake in shares of  Guardant Health in the 1st quarter valued at approximately $274,000.  Sei Investments Co. lifted its holdings in  Guardant Health by 15.8% in the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company's stock worth $4,023,000 after purchasing an additional 10,538 shares during the last quarter.  The Manufacturers Life Insurance Company lifted its holdings in  Guardant Health by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company's stock worth $32,922,000 after purchasing an additional 54,284 shares during the last quarter.  Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in  Guardant Health by 56.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company's stock worth $5,800,000 after purchasing an additional 40,209 shares during the last quarter. Institutional investors own  92.60% of the company's stock. </p><div><p><span></span><span>Get <strong>Guardant Health</strong> alerts:</span></p></div><h2>Guardant Health Trading Down 3.8%</h2><p>Shares of NASDAQ GH opened at $94.92 on Friday. The business has a fifty day simple moving average of $89.30 and a 200 day simple moving average of $97.90. The firm has a market capitalization of $12.59 billion, a price-to-earnings ratio of -28.00 and a beta of 1.48. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $120.74. </p><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. The company's quarterly revenue was up 39.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.62) EPS.  On average, research analysts anticipate that  Guardant Health, Inc. will post -2.87 earnings per share for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>GH has been the subject of several analyst reports. Raymond James Financial  restated an &#34;outperform&#34; rating and issued a $129.00 target price on shares of Guardant Health in a report on Monday, February 23rd. Leerink Partners boosted their target price on Guardant Health from $170.00 to $180.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, February 20th. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, May 8th. UBS Group  restated a &#34;buy&#34; rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Guardant Health in a report on Tuesday, April 21st. Nineteen research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $129.42.</p><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p><b>Get Our Latest Analysis on GH</b></p><h2>Insiders Place Their Bets</h2><p>In related news, CFO Michael Brian Bell sold 3,000 shares of the company's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $87.04, for a total value of $261,120.00. Following the completion of the transaction, the chief financial officer directly owned 43,601 shares in the company, valued at approximately $3,795,031.04. This represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Terilyn J. Monroe sold 3,832 shares of the company's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the completion of the sale, the insider owned 20,990 shares in the company, valued at $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,596 shares of company stock valued at $5,791,767 in the last ninety days. 5.60% of the stock is currently owned by insiders. </p><h2>Guardant Health Company Profile</h2> (Free Report)<p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.  </p><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p><h2>Read More</h2><ul><li>Five stocks we like better than Guardant Health</li><li>3 Stocks to Own If Gas Prices Keep Rising</li><li>3 Crucial Aerospace Component Makers That Analysts Love</li><li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li><li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2><p>Before you consider Guardant Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>World Investment Advisors acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) by purchasing 16,290 shares valued at approximately $1.66 million in Q4. Other investors, including AQR Capital Management and Sei Investments, also increased their holdings. Guardant Health's stock opened at $94.92, with a market cap of $12.59 billion. The company reported a quarterly revenue of $281.27 million, up 39.4% year-over-year, but missed EPS estimates. Analysts have mixed ratings, with a consensus price target of $129.42.</p>

Market Beat

Guardant Health

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Genomics Immunology and Healthcare ETF

iShares US Healthcare Providers

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

ALPS Medical Breakthrough

iShares US Medical Devices

SEI Investments

Manulife Financial

Raymond James Financial

Barclays

UBS Group AG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH